Granisetron Market By Dosage Form (Tablets, Injections, Transdermal Patches); By Application (Chemotherapy-Induced Nausea and Vomiting [CINV], Radiation-Induced Nausea and Vomiting [RINV], Postoperative Nausea and Vomiting [PONV]); By Route of Administration (Oral, Intravenous, Transdermal, Subcutaneous); By End User (Hospitals & Clinics, Oncology Centers, Ambulatory Surgical Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

What Is the Granisetron Market and How Is It Transforming Nausea and Vomiting Management?

The Global Granisetron Market was raised from USD 351.64 million in 2025 to USD 458.98 million by 2032, growing at a CAGR of 3.88%, according to Strategic Market Research. Demand is supported by the continued use of granisetron in preventing chemotherapy-induced nausea and vomiting (CINV), with oral tablets, injectable formulations, and transdermal patches providing treatment options across oncology care.

 

Chemotherapy-induced nausea and vomiting remains a significant clinical concern. A March 2026 systematic review published in Frontiers in Oncology reported that CINV risk can reach 60–80% in certain chemotherapy settings, while some patients continue to experience inadequate symptom control despite preventive treatment. Delayed nausea, occurring more than 24 hours after chemotherapy, remains particularly challenging and reinforces the importance of sustained antiemetic protection.

 

Longer-acting granisetron formulations are improving treatment convenience. Heron Therapeutics developed Sustol as an extended-release injectable formulation, while Cumberland Pharmaceuticals' Sancuso transdermal patch delivers approximately 3.1 mg of granisetron daily for up to seven days. The FDA-listed prescribing information confirms its use in preventing nausea and vomiting during moderately or highly emetogenic chemotherapy regimens lasting up to five consecutive days.

 

Granisetron remains an important part of oncology supportive care, particularly for patients requiring reliable nausea prevention across chemotherapy cycles. Continued use of established formulations and longer-acting delivery options is expected to support market demand through 2032, alongside advances in cancer treatment and supportive-care practices.

 

Which Granisetron Market Segments Are Leading and Emerging as Key Expansion Opportunities?

Leading Subsegments Across the Granisetron Market

By Dosage Form — Injections

Injections accounted for the largest share of the global Granisetron Market in 2025, representing approximately 47% of the total market, valued at USD 165.27 million. Granisetron injections are widely administered to prevent and manage nausea and vomiting associated with cancer chemotherapy, radiation therapy, and postoperative recovery. Their established role in hospital-based oncology care, particularly among patients receiving highly emetogenic chemotherapy, supports their leading market position. Intravenous administration also enables timely antiemetic intervention during intensive cancer treatment and surgical procedures.

By Application — Chemotherapy-Induced Nausea and Vomiting

Chemotherapy-Induced Nausea and Vomiting (CINV) accounted for an illustrative 70% share of the global Granisetron Market, equivalent to USD 246.15 million in 2025. Granisetron, a selective 5-HT3 receptor antagonist, is widely used to prevent and treat nausea and vomiting associated with chemotherapy. Its established role in supportive cancer care, particularly among patients receiving moderately and highly emetogenic chemotherapy, reinforces its clinical importance. Continued utilization across oncology treatment settings and integration into antiemetic treatment protocols support its substantial market contribution.

By Route of Administration — Intravenous

Intravenous (IV) administration accounted for an estimated 40% share of the global Granisetron Market, equivalent to USD 140.66 million in 2025. IV granisetron provides rapid antiemetic action for preventing and managing nausea and vomiting associated with cancer chemotherapy, radiation therapy, and surgical procedures. Its established use in oncology infusion centers, hospitals, and perioperative care supports its leading position. Direct administration into the bloodstream offers predictable drug delivery and timely symptom control, particularly among patients undergoing highly emetogenic chemotherapy or requiring immediate postoperative nausea management.

By End User — Hospitals & Clinics

Hospitals and clinics accounted for the largest share of the global Granisetron Market in 2025, representing approximately 55% of the end-user distribution, valued at USD 193.40 million. Their leading position reflects the central role of hospital oncology departments and clinical facilities in administering Granisetron to prevent chemotherapy-induced and postoperative nausea and vomiting. Hospitals and clinics remain the primary settings for Granisetron administration, patient monitoring, and treatment management, supported by established chemotherapy protocols, specialized oncology services, and supervised antiemetic treatment across inpatient and outpatient care facilities.

By Geography — North America

North America held the largest share of the global Granisetron Market in 2025, accounting for approximately 40%, equivalent to USD 140.66 million. Granisetron maintains an established position in regional oncology care, particularly for preventing chemotherapy-induced nausea and vomiting. Its continued utilization is supported by extensive cancer treatment infrastructure, established antiemetic prescribing protocols, and widespread availability of generic formulations. The United States remains the primary contributor, supported by high chemotherapy procedure volumes, comprehensive oncology care networks, and consistent adoption of supportive cancer therapies across healthcare facilities.

 

Potential Fastest-Expanding Subsegments Across the Granisetron Market

By Dosage Form — Transdermal Patches

Transdermal patches accounted for an illustrative 18.0% share of the global Granisetron Market in 2025, representing approximately USD 63.30 million in market value. Products such as Sancuso® provide sustained delivery of granisetron through the skin into systemic circulation, helping prevent chemotherapy-induced nausea and vomiting (CINV). The extended drug-release profile supports continuous antiemetic coverage during chemotherapy treatment, particularly for patients experiencing difficulty swallowing oral medications. The convenience of once-per-cycle patch application strengthens their clinical relevance in managing nausea and vomiting associated with chemotherapy regimens.

By Application — Chemotherapy-Induced Nausea and Vomiting

CINV, with an illustrative USD 246.15 million market size, remains a major potential expansion area. The WHO projects that annual global cancer diagnoses could approach 35 million by 2050. Continued development of antiemetic treatment protocols and long-acting formulations could support further granisetron utilization, although competing antiemetics influence its market prospects.

By Route of Administration — Subcutaneous

Subcutaneous administration accounted for an estimated 7% of the global Granisetron Market in 2025, representing USD 24.61 million. Extended-release subcutaneous granisetron, marketed as Sustol, provides sustained antiemetic activity for preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults undergoing moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination regimens. Its prolonged drug delivery supports nausea control across multiple days following chemotherapy, positioning subcutaneous formulations as a specialized treatment option within oncology supportive care and chemotherapy-related symptom management.

By End User — Oncology Centers

Oncology centers accounted for an illustrative 35% share of the global Granisetron Market, equivalent to USD 123.07 million in 2025. Their leading position reflects the widespread administration of granisetron as supportive care for patients undergoing chemotherapy and radiotherapy. Oncology centers routinely incorporate granisetron into antiemetic treatment protocols to prevent and manage chemotherapy-induced nausea and vomiting (CINV) and radiation-induced nausea and vomiting (RINV). Increasing outpatient chemotherapy procedures, structured antiemetic protocols, and continued emphasis on treatment tolerability reinforce granisetron utilization across specialized oncology facilities worldwide.

By Geography — Asia-Pacific

Asia-Pacific accounts for an estimated 22% of the global Granisetron Market, representing USD 77.36 million in 2025. The region is emerging as one of the fastest-growing geographical markets, supported by expanding oncology treatment facilities, increasing chemotherapy procedures, and wider access to supportive cancer care. China, India, and Japan remain important contributors to granisetron utilization, particularly for managing chemotherapy-induced nausea and vomiting. Growing hospital oncology networks, improving access to antiemetic therapies, and increasing availability of generic granisetron formulations are supporting sustained market expansion across Asia-Pacific.

 

Which Companies Are Shaping the Global Granisetron Market Through Pharmaceutical Innovation and Advanced Drug Delivery?

Cumberland Pharmaceuticals: Sancuso Expands Its Commercial Presence in Transdermal Therapy

Cumberland Pharmaceuticals is a specialty pharmaceutical company with a significant presence in transdermal granisetron therapy through Sancuso, an FDA-approved skin patch designed to prevent chemotherapy-induced nausea and vomiting. The company acquired U.S. commercial rights to Sancuso in January 2022 for an initial USD 13.5 million payment. Its transdermal technology enables continuous granisetron delivery over several days, reducing reliance on oral medication.

According to Cumberland's 2025 SEC filing, Sancuso generated approximately USD 11.91 million in revenue in 2025, compared with USD 9.01 million in 2024, an increase of 32.2%. This demonstrates the company's established commercial activity in differentiated granisetron formulations.

Heron Therapeutics: Sustol Faces a Commercialization Transition

Heron Therapeutics contributed to granisetron innovation through Sustol, an extended-release subcutaneous injection developed using its proprietary Biochronomer technology. This biodegradable polymer-based delivery system maintains therapeutic granisetron exposure for at least five days following a single injection. Sustol received FDA approval in August 2016 for preventing acute and delayed chemotherapy-induced nausea and vomiting in specified chemotherapy settings.

However, Heron's 2025 annual report disclosed a 6.7% decline in Sustol units sold and announced plans to wind down commercialization while evaluating potential product improvements and possible reintroduction as early as late 2027.

Fresenius Kabi: Injectable Granisetron Supply Supports Hospital Oncology Care

Fresenius Kabi is a global pharmaceutical and healthcare company involved in manufacturing and supplying injectable medications for hospital and clinical use. Its granisetron portfolio includes Granisetron Hydrochloride Injection, USP, available in a 1 mg/mL preservative-free, single-dose vial in the United States.

The company's role centers on providing standardized injectable antiemetic formulations for chemotherapy-related nausea and vomiting management. Its established pharmaceutical manufacturing and distribution infrastructure supports access to injectable therapies in clinical settings.

Other Key Companies and Their Roles in the Granisetron Market

• Grünenthal GmbH: Markets the Sancuso granisetron transdermal patch through Grünenthal Meds in the United Kingdom and participates in established-medicine commercialization across international markets.

• Hikma Pharmaceuticals: Supplies generic granisetron hydrochloride intravenous injections, including 1 mg/mL formulations, supporting access to hospital-administered antiemetic medicines.

• Teva Pharmaceutical Industries: Has manufactured generic granisetron tablets and injections, receiving FDA approval for 1 mg tablets and 1 mg/mL injectable formulations in January 2008.

• Aurobindo Pharma: Holds U.S. FDA approval for generic granisetron hydrochloride injections in 1 mg/mL and 4 mg/4 mL presentations, contributing to generic pharmaceutical supply.

• Dr. Reddy's Laboratories: Has pharmaceutical manufacturing and generic-drug capabilities relevant to antiemetic therapy, although its current granisetron-specific commercial activity was not independently confirmed.

• Cipla Limited: Operates in generic pharmaceuticals and oncology-related medicines, but its current granisetron-specific product portfolio and sales contribution were not independently verified.

 

Analyst Commentary: How Will Long-Acting Delivery and Generic Access Shape Granisetron Demand?

The granisetron market is witnessing a gradual shift from conventional oral and intravenous antiemetic treatments toward long-acting, patient-friendly drug-delivery systems. Key opportunities are emerging in extended-release subcutaneous injections, multi-day transdermal patches, and improved chemotherapy-induced nausea and vomiting management. The increasing global cancer burden, expansion of outpatient oncology services, and greater emphasis on patient comfort are supporting the adoption of convenient antiemetic therapies. Continued advancements in controlled-release formulations, personalized antiemetic protocols, and cost-effective generic medicines are expected to improve treatment accessibility, reduce administration frequency, and strengthen supportive cancer care.

 

Granisetron Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 351.64 Million
Revenue Forecast in 2032	USD 458.98 Million
Overall Growth Rate	CAGR of 3.88% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Dosage Form, By Application, By Route of Administration, By End User, By Geography
By Dosage Form	Tablets, Injections, Transdermal Patches
By Application	Chemotherapy-Induced Nausea and Vomiting [CINV], Radiation-Induced Nausea and Vomiting [RINV], Postoperative Nausea and Vomiting [PONV]
By Route of Administration	Oral, Intravenous, Transdermal, Subcutaneous
By End User	Hospitals & Clinics, Oncology Centers, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Continued granisetron use in chemotherapy supportive care, expanding outpatient oncology services, multi-day transdermal delivery, availability of generic oral and injectable formulations, emphasis on preventing acute and delayed nausea and vomiting
Customization Option	Available upon request